Related Experiment Videos
[The functional status of the sympathoadrenal system in hypertension patients being treated with captopril and
Insights
Endonasal dalargin electrophoresis (EDE) reduced sympathoadrenal system activity in hypertensive patients. EDE also enhanced captopril
Area of Science:
- Cardiology
- Pharmacology
- Endocrinology
Background:
- Hypertensive disease (HD) involves dysregulation of the sympathoadrenal system (SAS).
- Catecholamines (CA) and their precursors are key indicators of SAS activity.
- Assessing therapeutic effects on SAS is crucial for managing hypertension.
Purpose of the Study:
- To investigate the impact of endonasal dalargin electrophoresis (EDE) and captopril on urinary catecholamine excretion in hypertensive patients.
- To evaluate the efficacy of EDE as monotherapy and in combination with captopril for hypertension management.
- To determine the effect of captopril monotherapy on sympathoadrenal system activity.
Main Methods:
- Study included 87 patients with stage I and II hypertensive disease.
- Patients were divided into three groups based on therapy: EDE monotherapy (Stage I), captopril plus EDE (Stage II), and captopril monotherapy (Stage II).
- Urinary excretion of catecholamines and their precursors was measured.
Main Results:
- Endonasal dalargin electrophoresis (EDE) significantly reduced sympathoadrenal system (SAS) functional activity in stage I hypertensive patients.
- Combined therapy with EDE and captopril potentiated the hypotensive effect of captopril, leading to decreased norepinephrine excretion.
- Captopril monotherapy did not demonstrate a significant effect on the sympathoadrenal system condition.
Conclusions:
- EDE is effective in modulating SAS activity in early-stage hypertension.
- Combination therapy with EDE and captopril offers enhanced blood pressure control by influencing SAS.
- Captopril monotherapy alone does not impact SAS activity in the studied hypertensive patients.
Abstract:
The level of urinary excretion of catecholamines (CA) and their precursors was studied in 87 patients with stage I, II hypertensive disease (HD). Three groups were formed depending on the therapy option: group I comprised stage I HD patients in whom endonasal dalargin electrophoresis (EDE) was instituted, groups II and III were patients with stage II HD who were given a complex therapy with captopril plus EDE and monotherapy with captopril respectively. EDE led to a decline in the functional activity of the sympathoadrenal system (SAS) in stage I HD patients and potentiated a hypotensive effect of captopril resulting in diminution of excretion of norepinephrine. Captopril monotherapy failed to have an effect on the SAS condition.